Description of the Studies
Four of the 5 studies that evaluated for multiple co-occurring symptoms in patients with CRC used a descriptive, cross-sectional design.20–22,24 The fifth study used a descriptive, longitudinal, repeated-measures design.23 Across these 5 studies, retrospective data were used in 4.20–22,24 The sample sizes ranged from 104 patients21 to 5442 patients,22 and 3 of the 5 studies had less than 250 patients.21,23,24 Across the 5 studies, the weighted grand mean age was 59.5 years, and gender distribution was approximately equal. In 3 of the 5 studies,21,23,24 100% of the patients had CRC, and in 1 study,20 49.6% of the patients had colon cancer, and 50.4% had rectal cancer. In a fifth study,22 55.5% of the patients had CRC, and 44.5% had lung cancer.
All 5 studies were conducted in outpatient settings. Only 1 of the 5 studies reported the patients’ previous treatment regimens.20 All 5 studies reported that patients received CTX as one of their current treatment modalities. Only 2 studies reported symptom data on patients with and without targeted therapies.21,23 In terms of geographic locations, 2 studies were conducted in the United States,22,23 1 in Turkey,24 1 in Sweden,21 and 1 in China.20
Symptom Assessment and QOL Instruments
Symptom assessment instruments. A number of instruments were used to evaluate multiple co-occurring symptoms. All 5 studies used a multidimensional symptom assessment instrument (ie, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC-QLQ],22,24 Patient Care Monitor [PCM],23 MSAS,21 MDASI20). Two of the studies used the EORTC-QLQ,22,24 1 used the PCM,23 1 used the MDASI,20 and 1 used the MSAS.21 In addition, 2 studies22,24 utilized single symptom assessment instruments to evaluate additional symptoms (eg, anxiety [ie, State Trait Anxiety Inventory],24 depression [ie, Beck Depression Index,24 Center for Epidemiological Studies–Depression Scale22]).
Number and dimensions of symptoms assessed. The number of symptoms assessed ranged from a minimum of 7 symptoms22 to a maximum of 32.21 The 1 symptom dimension that was assessed across all 5 studies was severity. In 1 study,21 occurrence, frequency, severity, and distress were assessed, whereas in another study,20 interference from symptoms was assessed.
Functional status and QOL instruments. Generic and disease specific instruments were used to evaluate QOL in 3 of the 5 studies. In these studies, 1 study20 used a functional status instrument (ie, MDASI), and another study24 used a cancer-specific QOL instrument (ie, EORTC-QLQ). Only 1 study22 utilized both a generic (ie, Medical Outcomes Study Short-Form 36) and a disease specific (ie, EORTC-QLQ) instrument to evaluate the effects of multiple co-occurring symptoms on patients’ QOL.
Occurrence and Severity of Multiple Co-occurring Symptoms
Occurrence of multiple co-occurring symptoms. The occurrence of symptoms was evaluated in only 1 study.21 In this study, using the MSAS, the mean number of symptoms was 10.3 (range, 0–32; SD, 7.7). Using the MSAS classifications, the most common physical symptoms experienced by more than 40% of the patients were numbness/tingling in the hands/feet (64%), lack of energy (62%), feeling drowsy (49%), nausea (45%), shortness of breath (43%), and dry mouth (42%). The most common psychological symptoms were difficulty sleeping (46%) and worrying (44%).
Severity of multiple co-occurring symptoms. While the severity of multiple co-occurring was reported in all 5 studies, the findings were inconsistent. In 1 study,22 51% of patients reported at least 1 symptom of moderate/severe intensity, whereas in another study,23 it was noted that patients experienced moderate to severe symptoms (defined by a PCM item score of ≥4, at some point during second-line therapy), and 67% of patients reported fatigue as the most common symptom occurring at moderate to severe levels. In 1 study that evaluated 32 symptoms using the MSAS,21 for almost all of the symptoms, patients reported higher scores for frequency than for severity or distress. Of the 5 studies, only 1 study reported the range of severity scores for 7 symptoms.23 Compared with patients who received CTX with targeted therapies, patients who received CTX alone had a higher rate of moderate to severe nausea. In addition, compared with patients who received cetuximab, patients who received bevacizumab had significantly (P < .0001) lower (ie, better) rash scores than did patients in the CTX-only group.23
Associations Between Patient Characteristics and Multiple Co-occurring Symptoms
Associations between demographic characteristics and the severity of multiple co-occurring symptoms were evaluated in 2 studies.20,22 In 1 study,20 patients with more severe symptoms were 60 years or older, more likely to be female, had a lower body mass index, were single or divorced, were living in a suburban area, and had stage III colon cancer. In the second study,22 moderate or severe symptoms were significantly more likely to be associated with younger age, Hispanic or Latino ethnicity; being female, unmarried, and less educated; having a lower income; being uninsured; having more comorbidities; being diagnosed with late-stage cancer; and having received treatment more recently.
Association Between Multiple Co-occurring Symptoms and QOL Outcomes
The associations between multiple co-occurring symptoms and functional status or QOL outcomes were evaluated in 3 of the 5 studies.20,22,24 In 1 study,24 global QOL scores were significantly lower in patients with higher anxiety scores (State Trait Anxiety Inventory ≥45) and higher depressive symptom (Beck Depression Index ≥17) scores. In the second study,20 the authors reported that results from their study were consistent with other studies that demonstrated that higher self efficacy scores were associated with lower symptom severity and less symptom interference with daily life. Although 1 study utilized the EORTC-QLQ to evaluate multiple co-occurring symptoms,22 the investigators did not describe the relationships among these symptoms and QOL outcomes.
This review is the first to summarize the findings from studies that examined multiple co-occurring symptoms in CRC patients who received CTX alone or CTX with targeted therapies. Across the 5 studies included in this review, only 2 studies21,23 compared symptoms in patients who received CTX with or without targeted therapies. In addition, only 1 longitudinal study was identified.23 Given the larger number of patients with CRC, as well as the significant toxicities associated with CTX for CRC, it is surprising that only 5 studies have systematically evaluated symptom burden in these patients.
Symptom Assessment and QOL Instruments
Of the 5 studies identified for this review, only 2 used the same assessment instrument to assess symptoms in CRC patients (ie, EORTC-QLQ).22,24 This finding is not surprising, given the number of valid and reliable instruments that are available to assess multiple co-occurring symptoms in oncology patients.25,26 In addition, a question remains about the most appropriate symptoms to assess in CRC patients.27 Findings from this review suggest that little is known about the frequency, severity, and distress of symptoms in CRC patients and how these symptom dimensions change over time. Of note, across the 5 studies in this review, the most common instrument was the EORTC-QLQ, which contains a symptom severity scale with only 7 symptoms. However, the 2 studies that used the EORTC-QLQ22,24 did not report data on the severity of each symptom.
Occurrence and Severity of Multiple Co-occurring Symptoms
In the 1 study that reported on symptom occurrence, CRC patients reported an average of 10.3 of 32 symptoms using the MSAS. This finding is consistent with 2 systematic reviews,28,29 as well as findings from our research team7,8 and others30,31 that regardless of diagnosis oncology patients receiving active treatment experience a large number of unrelieved symptoms. In terms of the occurrence rates for specific symptoms, only 1 study reported the occurrence rates for unrelieved symptoms.21 The 5 most common symptoms were numbness/tingling in the hands/feet (64%), lack of energy (62%), feeling drowsy (49%), difficulty sleeping (46%), and nausea (45%).
A surprising finding is the lower occurrence rates for fatigue, which in most studies of patients receiving CTX32–35 occurs in more than 80% of patients. For example, in 1 study,32 fatigue was reported as the chief complaint by 51.1% of the patients with occurrence rates that ranged from 34% to 64%. In addition, the relatively high rate of numbness/tingling is consistent with 2 studies,36,37 in which a subset of patients with CRC who received a CTX regimen that contained oxaliplatin reported this symptom. Additional research is warranted to assess the occurrence rates for common symptoms in CRC patients across their disease trajectory. In addition, given the advances in CRC treatments, studies are needed that evaluate for differences in the occurrence rates for common symptoms in patients who do and do not receive targeted therapies.
Associations Between Demographic and Treatment Characteristics and Multiple Co-occurring Symptoms
Several demographic and treatment characteristics were associated with increases in symptom burden. For example, in 2 studies20,22 and consistent with previous studies of symptoms in oncology patients receiving CTX,35,37 being female was associated with more severe symptoms. However, given that only 2 studies evaluated for associations between demographic and treatment characteristics and symptom burden in CRC patients, a more detailed evaluation is warranted to identify high-risk patients.
Associations Between Multiple Co-occurring Symptoms and QOL Outcomes
Only 2 studies20,22 described associations between symptoms and QOL outcomes. While the data reported suggest that higher scores on anxiety and depression instruments were associated with lower global QOL scores22 and that positive correlations were found between patients’ ability to self-manage their symptoms and their functional status,20 no studies evaluated associations between multiple co-occurring symptoms and QOL in patients with CRC.
One of the primary purposes of this review was to compare symptom burden in CRC patients who received CTX alone or CTX with targeted therapies. While current estimates suggest that approximately 25% of CRC patients who have metastases at the time of diagnosis receive targeted therapies,38,39 only 1 study addressed this question. In this study, an instrument that evaluated only 8 specific symptoms (ie, rash, dry skin, itching, nail changes, nausea, vomiting, diarrhea, burning sensation in hands or feet) was used. The only difference identified was that compared with patients who received CTX with a targeted therapy, patients who received only CTX reported a higher rate of moderate to severe nausea. Additional research is warranted to determine if a differential symptom burden occurs in CRC patients who do or do not receive targeted therapies with their CTX. Moreover, future studies of multiple co-occurring symptoms need to use comprehensive symptom assessment instruments (ie, National Institutes of Health–supported advances in measurement science through PROMIS [the Patient Reported Outcomes Measurement Information System network])40,41 that evaluate multiple dimensions of the patient’s symptom experience.
Summary and Conclusions
Given that approximately 5% of Americans will be diagnosed with CRC in their lifetime,1 and more patients with CRC will receive targeted therapies with and without CTX,42 additional studies of multiple co-occurring symptoms are warranted. Future studies need to describe the occurrence, as well the severity, frequency, and distress of multiple co-occurring symptoms and their impact on QOL in CRC patients. In addition, changes in these symptom dimensions across the patients’ disease trajectory are warranted to be able to develop more targeted and effective symptom management interventions for these patients.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics 2015. CA Cancer J Clin
2. van Cutsem E, Nordlinger B, Cervantes A ESMO Guidelines Working Group. Advanced colorectal cancer
: ESMO Clinical Practice Guidelines for treatment. Ann Oncol
. 2010;21(suppl 5):v93–v97.
3. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov
4. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer
5. Ross JS, Schenkein DP, Pietrusko R, et al. Targeted therapies for cancer 2004. Am J Clin Pathol
6. Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician
7. Cataldo JK, Paul S, Cooper B, et al. Differences in the symptom experience of older versus younger oncology outpatients: a cross-sectional study. BMC Cancer
8. Ritchie C, Dunn LB, Paul SM, et al. Differences in the symptom experience of older oncology outpatients. J Pain Symptom Manage
9. Miaskowski C, Cooper BA, Melisko M, et al. Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy
10. Brown JK, Cooley ME, Chernecky C, Sarna L. A symptom cluster and sentinel symptom experienced by women with lung cancer. Oncol Nurs Forum
11. Kim E, Jahan T, Aouizerat BE, et al. Changes in symptom clusters in patients undergoing radiation therapy. Support Care Cancer
12. Wu HS, Davis JE, Natavio T. Fatigue and disrupted sleep-wake patterns in patients with cancer: a shared mechanism. Clin J Oncol Nurs
13. Dong ST, Butow PN, Costa DS, Lovell MR, Agar M. Symptom clusters in patients with advanced cancer: a systematic review of observational studies. J Pain Symptom Manage
14. Esper P. Symptom clusters in individuals living with advanced cancer. Semin Oncol Nurs
15. Gift AG. Symptom clusters related to specific cancers. Semin Oncol Nurs
16. Kim HJ, McGuire DB, Tulman L, Barsevick AM. Symptom clusters: concept analysis and clinical implications for cancer nursing. Cancer Nurs
. 2005;28(4):270–282; quiz 283–284
17. Cheng KK, Lee DT. Effects of pain, fatigue, insomnia, and mood disturbance on functional status and quality of life
of elderly patients with cancer. Crit Rev Oncol Hematol
18. Ferreira KA, Kimura M, Teixeira MJ, et al. Impact of cancer-related symptom synergisms on health-related quality of life
and performance status. J Pain Symptom Manage
19. Urban C, Anadkat MJ. A review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancers. J Gastrointest Oncol
20. Zhang MF, Zheng MC, Liu WY, Wen YS, Wu XD, Liu QW. The influence of demographics, psychological factors and self-efficacy on symptom distress in colorectal cancer
patients undergoing post-surgical adjuvant chemotherapy
. Eur J Oncol Nurs
21. Pettersson G, Berterö C, Unosson M, Börjeson S. Symptom prevalence, frequency, severity, and distress during chemotherapy
for patients with colorectal cancer
. Support Care Cancer
22. Walling AM, Weeks JC, Kahn KL, et al. Symptom prevalence in lung and colorectal cancer
patients. J Pain Symptom Manage
23. Walker MS, Pharm EY, Kerr J, Yim YM, Stepanski EJ, Schwartzberg LS. Symptom burden & quality of life
among patients receiving second-line treatment of metastatic colorectal cancer
. BMC Res Notes
24. Alacacioglu A, Binicier O, Gungor O, Oztop I, Dirioz M, Yilmaz U. Quality of life
, anxiety, and depression in Turkish colorectal cancer
patients. Support Care Cancer
25. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients. The M.D. Anderson Symptom Inventory. Cancer
26. Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer
27. Kirkova J, Davis MP, Walsh D, et al. Cancer symptom assessment instruments: a systematic review. J Clin Oncol
28. Gilbertson-White S, Aouizerat BE, Jahan T, Miaskowski C. A review of the literature on multiple symptoms
, their predictors, and associated outcomes in patients with advanced cancer. Palliat Support Care
29. Esther Kim JE, Dodd MJ, Aouizerat BE, Jahan T, Miaskowski C. A review of the prevalence and impact of multiple symptoms
in oncology patients. J Pain Symptom Manage
30. Akin S, Can G, Aydiner A, Ozdilli K, Durna Z. Quality of life
, symptom experience and distress of lung cancer patients undergoing chemotherapy
. Eur J Oncol Nurs
31. Yamagishi A, Morita T, Miyashita M, Kimura F. Symptom prevalence and longitudinal follow-up in cancer outpatients receiving chemotherapy
. J Pain Symptom Manage
32. Butt Z, Rosenbloom SK, Abernethy AP, et al. Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy
. J Natl Compr Canc Netw
33. Iop A, Manfredi AM, Bonura S. Fatigue in cancer patients receiving chemotherapy
: an analysis of published studies. Ann Oncol
34. Dhruva A, Dodd M, Paul SM, et al. Trajectories of fatigue in patients with breast cancer before, during, and after radiation therapy. Cancer Nurs
35. Brant JM, Beck SL, Dudley WN, Cobb P, Pepper G, Miaskowski C. Symptom trajectories during chemotherapy
in outpatients with lung cancer colorectal cancer
, or lymphoma. Eur J Oncol Nurs
36. Rosati G, Rossi A, Tucci A, Pizza C, Manzione L. Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer
. Ann Oncol
37. Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy
-induced neuropathy and its association with quality of life
among 2- to 11-year colorectal cancer
survivors: results from the population-based PROFILES registry. J Clin Oncol
38. Heinemann V, Douillard JY, Ducreux M, Peeters M. Targeted therapy
in metastatic colorectal cancer
—an example of personalised medicine in action. Cancer Treat Rev
39. El Zouhairi ME, Charabaty A, Pishvaian MJ. Molecularly targeted therapy
for metastatic colon cancer: proven treatments and promising new agents. Gastrointest Cancer Res
40. Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. J Clin Epidemiol
41. Jensen RE, Potosky AL, Reeve BB, et al. Validation of the PROMIS physical function measures in a diverse US population-based cohort of cancer patients. Qual Life Res
42. Edwards MS, Chadda SD, Zhao Z, Barber BL, Sykes DP. A systematic review of treatment guidelines for metastatic colorectal cancer
. Colorectal Dis
Keywords:Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved
Chemotherapy; Colorectal cancer; Quality of life; Symptoms; Targeted therapy